Sharon Bio-Medicine Ltd-$ (Delisted) share news and announcements
BSE: 532908Pharmaceuticals & Biotechnology
Last traded ₹3.30 on 28 Mar 2019
Delisted on 20 Feb 2024.
Sharon Bio-Medicine Ltd-$ disputes and clarifications
32 filed, newest first.
Aug 2023
Jun 2023
16 Jun · Legal
Exchange has sought clarification from Sharon Bio-Medicine Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not signed by authorized signatory/ies -2. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is awaited.
Mar 2023
16 Mar · Legal
Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 27-Feb-2023, regarding fire accident at the Company's manufacturing unit located at M/s Sharon Bio-Medicine Limited, Plot No L6, MIDC Area, Taloja, Panvel, Dist: Raigad, Maharashtra. On basis of above the Company is required to clarify following: 1. Insurance amount claimed and realized by the listed entity for the loss/damage;2. The actual amount of damage caused due to the natural calamity or other force majeure events;3. Details of steps taken to restore normalcy and the impact of the natural calamity/other force majeure events on production or service, financials of the entity.The response of the Company is awaited.
Feb 2023
24 Feb · Legal
Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 18-Feb-2023, regarding strikes/lockouts/disturbances. On basis of above the Company is required to clarify following: 1. In the event of settlement of the proceedings, details of such settlement including - terms of the settlement, compensation/penalty paid (if any) and impact of such settlement on the financial position of the listed entity.The response of the Company is awaited.
Jul 2020
30 Jul · Legal
Exchange has sought clarification from Sharon Bio-Medicine Limited for the quarter ended 31-Mar-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not signed by authorized signatory/ies The response of the Company is awaited.
Jun 2019
May 2019
30 May · Legal
Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Feb 2019
1 Feb · Legal
Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 28-Jan-2019, regarding 'Closure of operations of API plant '.". On basis of above the Company is required to clarify following: 1. Date of closure or estimated time of closure;2. Amount & percentage of turnover or revenue or income and net worth of the listed entity contributed by such unit or division during the last financial year;The response of the Company is awaited.
Jan 2019
29 Jan · Legal
Exchange had sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 09-Jan-2019, regarding that Ms. Komal Mota has been appointed as a Company Secretary & Compliance Officer w.e.f January 08, 2019." On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment)The response of the Company is enclosed.Ms. Komal Mota is a qualified Company Secretary and LLB having more than 4 years of experience and worked with Listed and Private Companies.11 Jan · Legal
Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 09-Jan-2019, regarding that Ms. Komal Mota has been appointed as a Company Secretary & Compliance Officer w.e.f January 08, 2019." On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment)The response of the Company is awaited.
Dec 2018
Jun 2018
4 Jun · Legal
Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not submitted within 30 minutes from end of board meeting. -2. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Mar 2018
7 Mar · Legal
Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 06-Mar-2018, regarding " Sharon Bio-Medicine Limited has informed the Exchange regarding 'Temporary Suspension of operations of API plant located at L-6, MIDC, Taloja, Dist. Raigad, Maharashtra 410208'.". On basis of above the Company is required to clarify following: 1. Factory/unit where the strike/lock out takes place including reasons for such strike. 2. Estimated impact on the production/operations in case of strikes/lock outs; 3. Whether loss/damage covered by insurance or not including amount; 4. Expected quantum of loss/damage caused; The response of the Company is awaited.
Dec 2017
11 Dec · Legal
Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not submitted within 30 minutes from end of board meeting. -2. Financial results not submitted as per Schedule III to the Companies Act, 2013 -3. Financial results not submitted as per Ind-AS format. -4. Reconciliation of profit and loss not submitted. -5. Reconciliation of Equity not submitted The response of the Company is awaited.
Sep 2017
12 Sep · Legal
12 Sep · Legal
The exchange asked on 11 Sep 2017
12 Sep · Legal
Exchange has sought clarification from Sharon Bio-Medicine Ltd on September 12, 2017, with reference to increase in Price. The reply is awaited.
Nov 2016
15 Nov · Legal
Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 14-Nov-2016, regarding "Sharon Bio-Medicine Limited has informed the Exchange that As per audited annual accounts the accumulated losses had exceeded the net worth of the company as on March 31, 2016 and therefore company has decided to make Reference to Board for Industrial and Financial Reconstruction (BIFR) in accordance with the provisions of Sick Industrial Companies (Special Provisions) Act, 1985.".On basis of above the Company is required to clarify following:1. Reasons for such a reference/petition;2. Impact of such reference/petition on listed entity.The response of the Company is awaited.
Sep 2016
20 Sep · Legal
Exchange has sought clarification from Sharon Bio-Medicine Ltd on September 20, 2016, with reference to news flashed on ET NOW dated September 20, 2016 stating "USFDA approves Sharon ....
Jun 2016
Jan 2016
14 Jan · Legal
Exchange has sought clarification from the Company with respect to announcement dated January 12, 2016, that the Board of Directors at their meeting held on January 12, 2016 have discussed the Closure of the subsidiary company M/s Yusur International FZE. On basis of above Company is required to clarify following -1. The amount and percentage of the turnover or revenue or income and net worth contributed by such entity during the last financial year; 2. Impact on the Company due to Closure.The response of the Company is awaited.
Jul 2015
9 Jul · Legal
Significant price movement has been observed in Sharon Bio-Medicine Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Sharon Bio-Medicine Limited has informed the Exchange that "From 29th June 2015 at one of the manufacturing plant at MIDC, Taloja near Navi Mumbai the US FDA Audit is concluded and we are understanding the outcome of US FDA Inspection. The US FDA Audit was completed on 7th July 2015 night."9 Jul · Legal
With reference to increase in Price, Sharon Bio-Medicine Ltd has Clarified to BSE as under: "Share Price of our Company has fallen from Rs. 90/- per share to Rs. 12.50 per share ....9 Jul · Legal
Exchange has sought clarification from Sharon Bio-Medicine Ltd with reference to increase in Price on July 09, 2015 The reply is awaited.
Mar 2015
17 Mar · Legal
Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated March 17 2015 that The Board of Directors at their meeting held on March 17, 2015 has decided to go with the restructuring of the debts of the company. On basis of above the Company is required to clarify following: a) Details and reasons for restructuring; b) Quantitative and/ or qualitative effect of restructuring; c) Details of benefit, if any, to the promoter/promoter group/group companies from such proposed restructuring; d) Brief details of change in shareholding pattern (if any)of all entities; e) Disclosure should include details like rationale for the scheme, the consideration involved, entities concerned in the transaction, (specifics on whether promoter / promoter group), clarity on whether it could be classified as a related party transaction, brief background of the business, financial impact, impact on shareholdings , additional approvals required before completion of transaction, effect of restructuring of debt or capital. The response of the Company is awaited.
Apr 2012